Premium
Biochemical modulation therapy for pancreatic cancer
Author(s) -
Hirata Koichi,
Mukaiya Mitsuhiro,
Yamamitsu Susumu,
Oikawa Ikuo,
Takashima Takeshi,
Katsuramaki Tadashi,
Sasaki Kazuaki,
Denno Ryuichi,
Shirasaka Tetsuhiko
Publication year - 1998
Publication title -
journal of hepato‐biliary‐pancreatic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 0944-1166
DOI - 10.1007/s005340050043
Subject(s) - medicine , pancreatic cancer , adverse effect , chemotherapy , oncology , gastrointestinal cancer , cisplatin , cancer , radiation therapy , stage (stratigraphy) , adenocarcinoma , fluorouracil , drug , gastroenterology , pharmacology , colorectal cancer , paleontology , biology
It is well known that the clinical course in most patients with advanced pancreatic cancer is not influenced substantially by chemotherapy and/or radiotherapy. However, new chemotherapy, based on the synergistic antitumor activities of 5‐fluorouracil (5‐FU) and cisplatin (CDDP) producing biochemical modulation in solid cancers diagnosed as adenocarcinoma, has recently been reported to be effective. In gastrointestinal cancers, the optimal concentrations of each drug and the duration of the anticancer effects, as well as adverse effects have been confirmed in pharmacodynamic studies. Our experience of this treatment for advanced pancreatic cancer (stage IV) indicates the usefulness of the antitumor effect in terms of both effect on the tumor size in unresectable patients and prognosis in resectable patients. These results were remarkable in patients diagnosed as stage IV b and/or curability C. Although there were adverse effects, none were severe. However, anything compromising the patient's quality of life must be prevented. Randomized prospective studies of the combination of 5‐FU and CDDP are expected in the near future.